Table 2 Summary of prednisolone treatment, cerebrospinal fluid (CSF) nucleated cell count, CSF total protein and neurodisability score (initial presentation to 12 month follow up)
|  | Prednisolone treatment (mg/kg SID) per day and duration of treatment | CSF cell count (cells/ μl) | CSF total protein (g/dl) | Neurodisability score | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Age (month) | Breed | Sex | Before RT 1 | During RT | After RT | Inital presentation | End of RT | 3 months after RT | Inital presentation | End of RT | 3 months after RT | Inital presentation | Beginnig of RT | End of RT | 3 months after RT | 6 months after RT | 9 months after RT | 12 months after RT |
1 | 8 | French Bulldog | fs | 2.1 (12 d) | 2.1 (2 d) | 0.25 (7 d) | 20 | Â | Â | 0.4 | Â | Â | 1 | 1 | 1 | / | / | / | / |
1.5 (4 d) | |||||||||||||||||||
0.5 (9 d) | |||||||||||||||||||
2 | 9 | Lagotto Romagnolo | m | 1.9 (22 d) | 0.9 2(2 d) | 0.13 (7 d) | 16.3 | 3 | 3 | 0.4 | 0.3 | 0.28 | 2.5 | 1 | 0 | 0 | 0 | 0 | 0 |
0.45 (5 d) | 0.07 (7 d) | ||||||||||||||||||
0.25 (7 d) | |||||||||||||||||||
3 | 36 | Pug | mk | 3.5 (21 d) | 2.2 (2 d) | 0.5 (14 d) | 126 | 4.3 | 4.33 | 1 | 0.3 | 0.33 | 3 | 4 | 2 | 1 | 1 | 1 | 1 |
2.2 (35 d) | 1.1(14 d) | 0.25 (21d) | |||||||||||||||||
0.13 (21d) | |||||||||||||||||||
0.07 (21d) | |||||||||||||||||||
4 | 72 | Weimaraner | fs | 4 (3 d) | 2 (2 d) | 0.2 (14d) | 4.7 | 0.2 | 0.17 | 0.4 | 0.1 | 0.13 | 4.5 | 6.5 | 1.5 | 0 | 0 | 0 | 0 |
0.8 (5 d) | 0.1 (14d) | ||||||||||||||||||
0.4 (7 d) | |||||||||||||||||||
5 | 156 | Mixed breed | m | 3.7 (2 d) | 2.4 (2 d) | 0.5 (21d) | 244 | 3 | 6 | 1.4 | 0.5 | 0.45 | 5.5 | 2.5 | 0 | 0 | 0 | 0 | 0 |
2.4 (8 d) | 0.9 (12 d) | 0.25 (7d) | |||||||||||||||||
0.13 (7d) | |||||||||||||||||||
6 | 15 | Chihuahua | fs | 4 (2 d) | 2 (2 d) | 0.5 (28d) | 77 | 2 | 2 | 0.5 | 0.16 | 0.3 | 5 | 1.5 | 0 | 0 | 0 | 1 | 0 |
2 (12 d) | 1 (12 d) | 0.3 (21d) | |||||||||||||||||
0.15 (21d) | |||||||||||||||||||